Eurogentec
License granted to fundamental RNAi patents
Published in Lab Law Weekly, August 19th, 2005
Alnylam Pharmaceuticals, Inc., (ALNY), an RNAi therapeutics company, announced that it has granted Eurogentec, a provider of genomics research solutions, a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"Life science reagent suppliers like Eurogentec continue to recognize that the Kreutzer-Limmer patent family represents fundamental intellectual property in the field of RNAi," said Vincent Miles, PhD, senior VP, Business Development of Alnylam...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2005-08-19)
More Articles from Lab Law Weekly
- AlphaRx, Inc.
Antibiotic development program uses nanoparticle delivery platform - Amrad
U.S. patent granted for asthma treatment - Brigham & Women's Hospital, Boston
Reports describe recent advances in cardiology research - Bristol-Myers Squibb Company
Agreement signed for sale of U.S., Canadian consumer medicines business - California Institute for Regenerative Medicine
Stem cell group creates governance subcommittee - Dey, LP
Pharma company reaches settlement with Connecticut on pricing litigation - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
